How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,081 results for

Sublingual Immunotherapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: A double-blind, placebo-controlled study (PubMed)

High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: A double-blind, placebo-controlled study Sublingual allergen-specific immunotherapy is a viable alternative to subcutaneous immunotherapy particularly attractive for use in children.This study investigated efficacy and safety of high-dose sublingual immunotherapy (SLIT) in children allergic to grass pollen in a randomized, double-blind, placebo-controlled trial.After a baseline

2012 EvidenceUpdates

182. Variation in allergen content in Sublingual Allergen Immunotherapy (SLIT) with house dust mites (HDM). (Full text)

Variation in allergen content in Sublingual Allergen Immunotherapy (SLIT) with house dust mites (HDM). Allergen immunotherapy is a treatment modality which can be applied using different vaccines. The aim of this study was to quantify and compare the allergen content of different house dust mites (HDM)' sublingual treatments and to review the evidence on their efficacy.Five sublingual allergen immunotherapy (SLIT) products were ordered and purchased at an ordinary pharmacy and masked

2015 Allergy PubMed

183. Sublingual immunotherapy in children and its potential beneficial collateral effect on respiratory tract infections. (PubMed)

Sublingual immunotherapy in children and its potential beneficial collateral effect on respiratory tract infections. Although directed to the control of allergic symptoms, a possible effect of sublingual immunotherapy (SLIT) on susceptibility to infections has been hypothesized. Two hundred sixty-five children aged between 3 and 4 years of age affected by allergic rhinitis completed a 6 year prospective case-control study. One hundred forty-three children after 2 years of SLIT reported a lower

2015 Current medical research and opinion

184. A major step forward for sublingual immunotherapy: the quality of 5-grass pollen tablet is recognized also in Italy (Full text)

A major step forward for sublingual immunotherapy: the quality of 5-grass pollen tablet is recognized also in Italy 25834457 2015 04 02 2018 11 13 1178-6965 8 2015 Journal of asthma and allergy J Asthma Allergy A major step forward for sublingual immunotherapy: the quality of 5-grass pollen tablet is recognized also in Italy. 25-7 10.2147/JAA.S82077 Ciprandi Giorgio G Medicine Department, IRCCS-Azienda Ospedaliera Universitaria San Martino, Genoa, Italy. eng Journal Article 2015 03 06 New

2015 Journal of asthma and allergy PubMed

185. Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial. (Full text)

Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial. We previously reported the initial results of the first multicenter, randomized, double-blind, placebo-controlled clinical trial of peanut sublingual immunotherapy (SLIT), observing a favorable safety profile associated with modest clinical and immunologic effects in the first year.We sought to provide long-term (3-year) clinical and immunologic outcomes for our peanut SLIT trial. Key end points

2015 The Journal of allergy and clinical immunology PubMed

186. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. (PubMed)

Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. The magnitude of effect of sublingual immunotherapy for house dust mite (HDM)-induced allergic rhinitis with or without conjunctivitis is uncertain, partly because there are few well-controlled trials with well-defined doses.We sought to determine the dose-related efficacy and onset of action of the HDM sublingual immunotherapy tablet MK-8237 (Merck/ALK-Abelló) using

2015 The Journal of allergy and clinical immunology

187. Immunological parameters in prophylactic sublingual immunotherapy in asymptomatic subjects sensitized to Japanese cedar pollen. (Full text)

Immunological parameters in prophylactic sublingual immunotherapy in asymptomatic subjects sensitized to Japanese cedar pollen. This study aims to examine the immunological parameters, focusing IL-10 productivity, in prophylactic sublingual immunotherapy (SLIT) in asymptomatic subjects sensitized to Japanese cedar pollen (JCP).This study was conducted as part of a randomized, double-blind, placebo-controlled, multiple center trial, and was performed for two consecutive pollen seasons in 2012

2015 Allergology international : official journal of the Japanese Society of Allergology PubMed

188. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. (Full text)

A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. The capacity of sublingual allergen immunotherapy (SLIT) to provide effective symptom relief in pollen-induced seasonal allergic rhinitis is often questioned, despite evidence of clinical efficacy from meta-analyses and well-powered, double-blind, placebo-controlled randomized clinical trials. In the absence of direct, head-to-head, comparative trials of SLIT

2014 BMC Medicine PubMed

189. High-dose sublingual immunotherapy in patients with uncontrolled allergic rhinitis sensitized to pollen: a real-life clinical study. (PubMed)

High-dose sublingual immunotherapy in patients with uncontrolled allergic rhinitis sensitized to pollen: a real-life clinical study. High-dose pollen sublingual immunotherapy (SLIT) is indicated in patients with moderate to severe allergic rhinitis (AR), especially those who are unable to control their disease with pharmacotherapy. We explore the use of high-dose SLIT in patients with severe AR and sensitized to pollen, in real-life clinical practice. We also analyzed the effect on asthma.This

2014 International forum of allergy & rhinology

190. Effects of sublingual immunotherapy for Dermatophagoides farinae on Th17 cells and CD4(+) CD25(+) regulatory T cells in peripheral blood of children with allergic asthma. (PubMed)

Effects of sublingual immunotherapy for Dermatophagoides farinae on Th17 cells and CD4(+) CD25(+) regulatory T cells in peripheral blood of children with allergic asthma. Sublingual immunotherapy is becoming a more common treatment for allergic diseases, particularly in pediatric clinics. This type of treatment is highly effective for Dermatophagoides farinae allergy, but the mechanisms resulting in immune tolerance have not been investigated. We explored the effects of sublingual immunotherapy (...) with D. farinae drops on populations of subsets of T immune cells, specifically Th17 cells and CD4(+) CD25(+) regulatory T cells (Treg cells), in peripheral blood of children with allergic asthma.We assessed immune cell populations in 60 patients allergic to D. farinae who were randomly divided into 2 groups: a treatment group (n = 30) and a control group (n = 30), treated with sublingual administration of D. farinae drops or placebo, respectively, for 48 weeks. Clinical symptoms of asthma were

2014 International forum of allergy & rhinology

191. Sublingual immunotherapy: current concepts for the U.S. practitioner. (PubMed)

Sublingual immunotherapy: current concepts for the U.S. practitioner. Estimates of the prevalence of allergic rhinitis in the United States range from 20% to 40%. Allergen-specific immunotherapy (SIT) is typically recommended for patients with allergic rhinitis who fail medical treatment, desire an alternative to pharmacotherapy, or would like to pursue therapy that can potentially change the natural history of the disease. Sublingual immunotherapy (SLIT) involves dosing the allergen under (...) of SLIT for inhalant allergic rhinitis.SLIT is a safe and effective immune modulating treatment that decreases symptoms and medication use for allergic rhinitis. Further study is needed to determine the relative effectiveness of SLIT compared to subcutaneous immunotherapy, the role of multiple-allergen vs single-allergen SLIT, the use of SLIT in special populations (pregnancy, patients taking beta-blockers), and optimal dosing of U.S. products.SLIT is safe and effective, and offers a convenient

2014 International forum of allergy & rhinology

192. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. (PubMed)

Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. Sublingual immunotherapy with liquid extracts provides an appealing alternative to subcutaneous immunotherapy for the treatment of allergic rhinoconjunctivitis (ARC), but a lack of robust evidence has deterred its use in North America.To determine the efficacy and tolerability of standardized glycerinated short ragweed sublingual allergen immunotherapy (...) -related oromucosal local application site reactions occurred early and were transient and self-limited. No anaphylaxis occurred.This is the first successful North American confirmatory phase 3 clinical trial to demonstrate the safety and efficacy of a sublingual standardized ragweed allergen immunotherapy liquid extract for the treatment of ARC.Copyright © 2013 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

2014 Journal of Allergy and Clinical Immunology

193. Dropouts in sublingual allergen immunotherapy trials - a systematic review. (Full text)

Dropouts in sublingual allergen immunotherapy trials - a systematic review. Participant dropouts can reduce the power of allergen immunotherapy clinical trials. Evaluation of the dropout rate and reasons for dropout are important not only in the planning of clinical studies but are also relevant for adherence to immunotherapy in daily clinical practice. A systematic review was carried out in order to establish the overall dropout rate among published double-blind, placebo-controlled randomized (...) clinical trials of sublingual immunotherapy for respiratory allergic diseases. Dropouts were analysed in regards to allergen, formulation, treatment schedule, participant age, study size, number of centres and type of allergic disease. Relative dropout rates in placebo and active groups as well as reasons for dropout were also assessed. A total of 81 studies, comprising 9998 patients, were included. Dropout rates in sublingual immunotherapy controlled studies do not appear to be a major problem

2014 Allergy PubMed

194. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets.

Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets. Lais® allergoid tablets contain allergens that are modified by carbamylation. Due to their modified chemical structure, they are suitable for sublingual immunotherapy (SLIT) (13, 16, 17, 24). Based on their small molecule size of 12 to 40 kDa (...) observed. Severe systemic side effects did not occur. On the basis of the trial results summarized in this review, we suggest that SLIT using Lais® sublingual tablets is an effective and well-tolerated form of treatment.

2014 Acta dermatovenerologica Alpina, Pannonica, et Adriatica

195. The Efficacy of Sublingual Immunotherapy with Dermatophagoides farinae Vaccine in a Murine Atopic Dermatitis Model. (PubMed)

The Efficacy of Sublingual Immunotherapy with Dermatophagoides farinae Vaccine in a Murine Atopic Dermatitis Model. Sublingual immunotherapy (SLIT) is a potential treatment for house dust mite-induced atopic dermatitis (AD). However, the mechanisms of action are not clear.To establish a mouse model of AD in order to study the effect and mechanisms of SLIT.Mice were sensitized and subsequently challenged by repeated cutaneous application of Der f allergen extract. Sensitized mice were SLIT

2014 Clinical and Experimental Allergy

196. Comments on: "Anaphylaxis caused by in-season switchover of sublingual immunotherapy formulation" (PubMed)

Comments on: "Anaphylaxis caused by in-season switchover of sublingual immunotherapy formulation" 25298112 2015 10 22 2018 12 02 1399-3038 25 7 2014 Nov Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology Pediatr Allergy Immunol Comments on: 'Anaphylaxis caused by in-season switchover of sublingual immunotherapy formulation'. 715-6 10.1111/pai.12290 Yalaoui Tarik T Stallergenes, Antony, France. de Beaumont Olivier O eng Letter

2014 Pediatric Allergy and Immunology

197. Effectiveness of subcutaneous versus sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. (PubMed)

Effectiveness of subcutaneous versus sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. Allergen-specific immunotherapy is widely used in the management of patients with allergic rhinoconjunctivitis and asthma, but the best route of delivery is unclear.We performed a systematic review of studies with head-to-head comparison of effectiveness and safety of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT (...) compared the effectiveness and safety of SCIT and SLIT. The effectiveness of the 2 forms of immunotherapy in managing allergic asthma and rhinoconjunctivitis were reported in 4 and 6 clinical trials, respectively. Low-grade evidence supports greater effectiveness of SCIT than SLIT for asthma symptom reduction and also at reducing a combined measure of rhinitis symptoms and medication use. Moderate-grade evidence supports greater effectiveness of SCIT than SLIT for nasal and/or eye symptom reduction

2014 The journal of allergy and clinical immunology. In practice

198. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. (PubMed)

Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. In North America, few studies have evaluated sublingual immunotherapy for allergic rhinitis with or without conjunctivitis (AR/C); pediatric data are sparse. The authors report findings from the largest published immunotherapy trial yet conducted in adults and children.To evaluate grass sublingual immunotherapy tablet (MK-7243) treatment in subjects with AR/C.North American subjects (5-65

2014 Asthma & Immunology

199. Efficacy of Sublingual Immunotherapy for Allergic Asthma: Retrospective Meta-Analysis of Randomized, Double-Blind, and Placebo-Controlled Trials. (PubMed)

Efficacy of Sublingual Immunotherapy for Allergic Asthma: Retrospective Meta-Analysis of Randomized, Double-Blind, and Placebo-Controlled Trials. Allergen-specific immunotherapy (SIT) is the only available curative choice with a disease-modifying effect against respiratory allergies. The efficacy of SIT via the sublingual route was demonstrated by a number of clinical trials. This meta-analysis was performed to investigate the clinical efficacy and safety of sublingual-specific immunotherapy (...) [standardized mean difference (SMD), -0.74; P=0.006] and medication scores (SMD, -0.78; P=0.02) compared with placebo. SLIT offers a better clinical response in mite sensitive asthmatics but without confirmed proof from subgroup analyses. Prolonged duration of treatment for more than 12 months brings no additive effects. Improvement in the skin prick test was also observed following immunotherapy. There was no consistent effect on forced expiratory volume in 1 s, serum levels of antigen-specific

2014 The clinical respiratory journal

200. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. (PubMed)

Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. Sublingual immunotherapy with liquid extracts provides an appealing alternative to subcutaneous immunotherapy for the treatment of allergic rhinoconjunctivitis (ARC), but a lack of robust evidence has deterred its use in North America.To determine the efficacy and tolerability of standardized glycerinated short ragweed sublingual allergen immunotherapy (...) -related oromucosal local application site reactions occurred early and were transient and self-limited. No anaphylaxis occurred.This is the first successful North American confirmatory phase 3 clinical trial to demonstrate the safety and efficacy of a sublingual standardized ragweed allergen immunotherapy liquid extract for the treatment of ARC.Copyright © 2013 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

2014 The Journal of allergy and clinical immunology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>